Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection

다국어 초록 (Multilingual Abstract)

Background/Aims: The aim of this study was to analyze the clinical impacts of obesity and hazardous alcohol use on the outcome of entecavir (ETV) therapy in chronic hepatitis B (CHB) patients.
Methods: The medical records of 88 treatment-naïve patients who were diagnosed with CHB and received ETV between March 2007 and September 2009 were analyzed retrospectively. Body mass index (BMI) values and Alcohol Use Disorders Identifi cation Test (AUDIT) scores were obtained at 6 months after the initiation of ETV (0.5 mg daily) treatment.
Results: A BMI of 25 kg/m2 or more was recognized as an indicator of obesity, and a total AUDIT score of 8 or more was recognized as an indicator of hazardous alcohol use. Of the cohort, 24 patients (27.3%) were obese and 17 (19.3%) were hazardous alcohol users. The rate of seroconversion, alanine aminotransferase (ALT) normalization, and hepatitis B virus (HBV)-DNA negativity (<300 copies/mL) at 3, 6, and 12 months of treatment did not differ significantly between the normal-BMI and high-BMI groups. Moreover, the rate of seroconversion and HBV-DNA negativity at 3, 6, and 12 months of treatment did not diff er signifi cantly between the nonhazardous and hazardous alcohol users. However, the frequency of ALT normalization at 12 months was signifi cantly lower among hazardous alcohol users (91.5% vs. 70.6%; P =0.033).
Conclusions: Obesity and hazardous alcohol drinking have no significant impact on the outcome of ETV treatment.
However, the ALT normalization rate at 12 months after initiation of ETV treatment was signifi cantly lower among the hazardous alcohol users. (Clin Mol Hepatol 2012;18:195-202)

다국어 초록 (Multilingual Abstract)

Background/Aims: The aim of this study was to analyze the clinical impacts of obesity and hazardous alcohol use on the outcome of entecavir (ETV) therapy in chronic hepatitis B (CHB) patients.
Methods: The medical records of 88 treatment-naïve patients who were diagnosed with CHB and received ETV between March 2007 and September 2009 were analyzed retrospectively. Body mass index (BMI) values and Alcohol Use Disorders Identifi cation Test (AUDIT) scores were obtained at 6 months after the initiation of ETV (0.5 mg daily) treatment.
Results: A BMI of 25 kg/m2 or more was recognized as an indicator of obesity, and a total AUDIT score of 8 or more was recognized as an indicator of hazardous alcohol use. Of the cohort, 24 patients (27.3%) were obese and 17 (19.3%) were hazardous alcohol users. The rate of seroconversion, alanine aminotransferase (ALT) normalization, and hepatitis B virus (HBV)-DNA negativity (<300 copies/mL) at 3, 6, and 12 months of treatment did not differ significantly between the normal-BMI and high-BMI groups. Moreover, the rate of seroconversion and HBV-DNA negativity at 3, 6, and 12 months of treatment did not diff er signifi cantly between the nonhazardous and hazardous alcohol users. However, the frequency of ALT normalization at 12 months was signifi cantly lower among hazardous alcohol users (91.5% vs. 70.6%; P =0.033).
Conclusions: Obesity and hazardous alcohol drinking have no significant impact on the outcome of ETV treatment.
However, the ALT normalization rate at 12 months after initiation of ETV treatment was signifi cantly lower among the hazardous alcohol users. (Clin Mol Hepatol 2012;18:195-202)

참고문헌 (Reference)

1 명형준, "만성 B형간염 환자에 대한 초치료제로서 엔테카비어의 항바이러스 효과와 그 예측인자" 대한간학회 16 (16): 57-65, 2010

2 Skipsey K, "Utility of the AUDIT for identification of hazardous or harmful drinking in drug-dependent patients" 45 : 157-163, 1997

3 Patton HM, "The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients" 40 : 484-490, 2004

4 Babor TF, "The Alcohol Use Disorders Identification Test: Guideline for use in Primary Care" World Health Organization 1-41, 2001

5 Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level" 295 : 65-73, 2006

6 Hassan MM, "Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus" 36 : 1206-1213, 2002

7 Lee JM, "Quantitative Hepatitis B Surface Antigen and Hepatitis B e Antigen Titers in Prediction of Treatment Response to Entecavir" JOHN WILEY & SONS INC 53 (53): 1486-1493, 2011

8 Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load" 130 : 678-686, 2006

9 Loomba R, "Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men" 8 : 891-898.e1-2, 2010

10 Lee KS, "Management of chronic hepatitis B" 13 : 447-488, 2007

11 Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B" 125 : 1714-1722, 2003

12 Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy" 49 : 1503-1514, 2009

13 Thomopoulos KC, "Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C" 17 : 149-153, 2005

14 Charlton MR, "Impact of obesity on treatment of chronic hepatitis" 43 : 1177-1186, 2006

15 Cindoruk M, "Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection" 41 : 513-517, 2007

16 Pratt DS, "Evaluation of abnormal liver-enzyme results in asymptomatic patients" 342 : 1266-1271, 2000

17 McMahon BJ, "Epidemiology and natural history of hepatitis B" 25 (25): 3-8, 2005

18 Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B" 354 : 1011-1020, 2006

19 Harrison SA, "Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C" 3 : 604-609, 2005

20 Kim HJ, "Comparison between clevudine and entecavir treatment for antiviralnaïve patients with chronic hepatitis B" 30 : 834-840, 2010

21 Geissler M, "Chronic ethanol effects on cellular immune responses to hepatitis B virus envelope protein: an immunologic mechanism for induction of persistent viral infection in alcoholics" 26 : 764-770, 1997

22 Larkin J, "Chronic ethanol consumption stimulates hepatitis B virus gene expression and replication in transgenic mice" 34 : 792-797, 2001

23 Yu MW, "Body-mass index and progression of hepatitis B: a population-based cohort study in men" 26 : 5576-5582, 2008

24 Donato F, "Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women" 155 : 323-331, 2002

25 Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B" 354 : 1001-1010, 2006